PLX

2.59

1.97% 0.05

Pre-mercato: 2.58 -0.010 -0.39%

Protalix BioTherapeutics Inc. (PLX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Forum Previsione Frazionamento azionario

Precedente Chiudi:

$2.54

Aprire:

$2.55

Volume 24 ore:

385.68K

Relative Volume:

0.57

Capitalizzazione di mercato:

$198.20M

Reddito:

$63.63M

Utile/perdita netta:

$10.62M

Rapporto P/E:

51.80

EPS:

0.05

Flusso di cassa netto:

$-8.64M

1 W Prestazione:

+4.44%

1M Prestazione:

+11.16%

6M Prestazione:

+153.92%

1 anno Prestazione:

+108.87%

Intervallo 1D:

$2.54

$2.61

Intervallo di 1 settimana:

$2.43

$2.62

Portata 52W:

$0.8214

$2.76

Protalix BioTherapeutics Inc. Stock (PLX) Company Profile

Nome

Protalix BioTherapeutics Inc.

Settore

Healthcare (1161)

Industria

Biotechnology (676)

Telefono

972 4 988 9488

Indirizzo

2 Snunit Street, Science Park PO Box 455, Karmiel

Dipendente

190

Cinguettio

@Protalix_Bio

Prossima data di guadagno

2025-03-17

Ultimi documenti SEC

PLX's Discussions on Twitter

Confronta PLX con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
PLX Protalix BioTherapeutics Inc.	2.59	198.20M	63.63M	10.62M	-8.64M	0.05
VRTX Vertex Pharmaceuticals Inc	483.49	124.48B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	625.60	67.45B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	583.62	35.60B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	266.83	34.53B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	274.78	29.15B	3.81B	-644.79M	-669.77M	-6.24

Protalix BioTherapeutics Inc. Stock (PLX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2020-06-08	Reiterato	H.C. Wainwright	Buy
2017-04-17	Reiterato	Rodman & Renshaw	Buy
2016-04-04	Iniziato	Rodman & Renshaw	Buy
2015-04-23	Aggiornamento	Jefferies	Hold → Buy
2014-11-12	Reiterato	R. F. Lafferty	Buy
2014-01-24	Iniziato	R. F. Lafferty	Buy
2012-05-02	Downgrade	Canaccord Genuity	Buy → Hold
2012-05-02	Reiterato	Oppenheimer	Outperform
2012-04-30	Downgrade	Auriga	Buy → Hold
2011-10-13	Iniziato	Morgan Joseph	Hold
2011-03-17	Downgrade	WBB Securities	Strong Buy → Buy
2010-11-09	Reiterato	Oppenheimer	Outperform
2010-10-14	Reiterato	UBS	Buy
2009-12-02	Reiterato	Hapoalim	Outperform
2009-09-22	Iniziato	Canaccord Adams	Buy
2009-09-02	Iniziato	Hapoalim	Outperform
2008-12-01	Reiterato	Oppenheimer	Outperform
2008-03-11	Iniziato	UBS	Buy
2007-11-20	Iniziato	CIBC Wrld Mkts	Sector Outperform

Mostra tutto

Protalix BioTherapeutics Inc. Borsa (PLX) Ultime notizie

Apr 01, 2025

Virtu Financial LLC Has $64,000 Stock Holdings in Protalix BioTherapeutics, Inc. (NYSE:PLX) - Defense World

Apr 01, 2025

Mar 26, 2025

[Latest] Global Fabry Disease Treatment Market Size/Share Worth USD 7.02 Billion by 2034 at a 9.8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value) - GlobeNewswire Inc.

Mar 26, 2025

Protalix Biotherapeutics is developing innovative treatments for rare diseases with its proprietary ProCellEx plant cell expression system - Proactive financial news

Mar 26, 2025

Protalix BioTherapeutics And 2 Other Promising Penny Stocks - simplywall.st

Mar 26, 2025

Mar 24, 2025

Protalix to present at iAccess Alpha Virtual Investment Conference 2025 - Proactive Investors

Mar 24, 2025

Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025 - Nasdaq

Mar 24, 2025

Mar 22, 2025

Is Protalix BioTherapeutics (PLX) The High Growth Low Debt Stock to Invest in Now? - Insider Monkey

Mar 22, 2025

What is Zacks Small Cap’s Forecast for PLX FY2025 Earnings? - The AM Reporter

Mar 22, 2025

Mar 21, 2025

Nvidia, Nike, Sarepta Therapeutics, Protalix and more analyst calls of the week - Proactive Investors

Mar 21, 2025

Protalix Biotherapeutics chairman discusses breakthrough in gout treatment, drug pipelineICYMI - Proactive Investors USA

Mar 21, 2025

FY2025 Earnings Estimate for PLX Issued By Zacks Small Cap - Defense World

Mar 21, 2025

Mar 20, 2025

Protalix BioTherapeutics (NYSE:PLX) Stock Rating Lowered by StockNews.com - Defense World

Mar 20, 2025

Protalix Stock (PLX) Grabbing Attention with Record Revenue Surge - markets.businessinsider.com

Mar 20, 2025

Mar 18, 2025

Small cap wrap: Fineqia, Candel Therapeutics, Ocean Power Technologies, Protalix Biotherapeutics... - Proactive Investors UK

Mar 18, 2025

Protalix Biotherapeutics gains momentum: analysts see long-term upside - Proactive Investors USA

Mar 18, 2025

Protalix BioTherapeutics pipeline eyes gout treatment as financial strength fuels future growth - Proactive financial news

Mar 18, 2025

Protalix BioTherapeutics : Chiesi Global Rare Diseases Announces Multiple Presentations on pegunigalsidase alfa and Fabry Disease at the 21st Annual WORLDSymposium™ Research Meeting - Marketscreener.com

Mar 18, 2025

Protalix Biotherapeutics reports record revenue in 2024, advances gout treatment candidate - Proactive Investors UK

Mar 18, 2025

Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 18, 2025

PLX: 2024 Results - Yahoo Finance

Mar 18, 2025